40O Phase I/Ib open-label study of an HER2-targeted T cell engager (TCE)‒SAR443216 in patients (pts) with advanced solid tumors: Intravenous (IV) dose-escalation results
Year: 2025
Type: article
Study design: Clinical Trial
Abstract: SAR443216 is a novel trispecific antibody targeting HER2-expressing tumors. It activates T cells for cytolysis of HER2-positive (HER2+) cancer cells by binding to CD3, CD28, and HER2. Here, we present safety, PK, and biomarker data for 9 dose levels (DLs) of SAR443216 in pts with advanced solid tumors in the IV dose-escalation cohort of a first-in-human open-label phase 1/1b trial (NCT05013554).
Source: ESMO Open
Authors: E. Calvo, V. Moreno Garcia, D-Y. Oh, M.H. Ryu, E. Garralda, W-P. Chung, L-Y. Bai, K.I. Rojas Laimito, O. Yildirim, S. Masciari, G. Mi, L. Wang, D. Carene, S. Gailhac, R. Perez, P. Kanlikilicer, B. Buday, F. Rharbaoui, G. Abbadessa, E.E. Dumbrava
Institutions: Hospital Universitario HM Sanchinarro, Hospital Universitario Fundación Jiménez Díaz, Seoul National University Hospital, Asan Medical Center, University of Ulsan, Vall d'Hebron Hospital Universitari, National Cheng Kung University, China Medical University, Sanofi (United States), Sanofi (France), The University of Texas MD Anderson Cancer Center
Language: English
Topic: HER2/EGFR in Cancer Research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,910
OpenAlex ID: W4408216872